NCT03569631View on ClinicalTrials.gov

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Fragile X SyndromeFXSFra(X) Syndrome
Interventions
DRUG

BPN14770

25 mg BPN14770 capsules

DRUG

Placebo

Placebo capsules to mimic 25 mg BPN14770 capsules

Trial Locations (1)

60612

Rush University Medical Center, Chicago

Sponsors
All Listed Sponsors
lead

Tetra Discovery Partners

INDUSTRY

NCT03569631 - A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome | Biotech Hunter | Biotech Hunter